Aim: SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine) is an atypical dopamine receptor-1 (D 1 receptor) agonist, which exhibits many D 1 receptor-independent effects. In the present work, we examined the effects of SKF83959 on monoaminergic transporters in vitro and its anti-depressant activity in vivo. Methods: Human serotonin transporter (SERT), norepinephrine transporters (NET) or dopamine transporters (DAT) were stably expressed in CHO cells. The uptake kinetics of SERT, NET, and DAT were examined using 
Introduction
Depression is a severe and chronic mental disorder that affects a large population worldwide [1, 2] . The development of effective anti-depressants with less adverse effects remains a challenge in pharmaceutical research. Within the past few decades, biogenic amine uptake inhibitors have been the mainstay for the treatment of depression, such as the prototypical tricyclic anti-depressants, the selective serotonin uptake inhibitors and the so-called "second" generation dual serotonin/ norepinephrine uptake inhibitors with a "cleaner" side effect profile [3] . Despite these advances, all these drugs often require 3 weeks to take effect. Moreover, nearly 30%-40% of patients with depression were not responsive to these therapies [4] . Recent studies have shown that a compound producing an immediate increase in synaptic dopamine concentrations would result in a more rapid onset of relief and a shortening or elimination of the therapeutic lag [5] . Thus, triple uptake inhibitors have become a focal point in anti-depressant drug development. Furthermore, some of these drugs have shown promising responses in clinical trials [6] [7] [8] [9] . The atypical dopamine receptor-1 (D 1 receptor) agonist, 3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) has shown various biological functions in vitro and in intact animals. Unlike the typical D 1 receptor agonists, SKF83959 does not stimulate the production of cyclic adenosine monophosphate (cAMP) via D 1 -like receptor-mediated activation of the G s protein [10] [11] [12] [13] ; instead, it selectively activates the G q protein via the D 1 -like receptor, which results in the production of inositol triphosphate [14] [15] [16] [17] [18] [19] [20] . In animals, this drug was found to increase eye blinking in monkeys and rats and to elicit excellent antiParkinsonism effects in a primate model as well as in a unilateral-lesioned rodent model [21] [22] [23] . The anti-Parkinsonism effects were shown to be independent of D 1 dopamine receptor-stimulated cAMP and may be associated with the drug-activated G q /phospholipase C pathway [23, 24] . In addition to the receptor-mediated events, recent data also indicated that the D 1 receptor-independent pharmacological effects also played important roles in SKF83959-mediated biological responses. For example, we found that potent neuronal protection of the drug was only partially dependent on the D 1 receptor [25] and that SKF83959 blocked Na + channels [26] , modulated the delayed rectifier K + channels [27] and promoted the spontaneous release of glutamate in rat somatosensory cortical neurons [28] . In the present work, we examined whether SKF83959 effectively inhibited the uptake activity of the serotonin transporter (SERT), norepinephrine transporter (NET) and dopamine transporter (DAT), by functioning as a potent triple uptake inhibitor. Moreover, we also examined the anti-depressant activity of SKF83959 in vivo.
Materials and methods

Animals
Male C57BL/6J mice, weighing 18-20 g, were purchased from Shanghai Laboratory Animal Co, Ltd (Shanghai, China) and were housed in plastic cages (temperature: 21±1 °C) with air exchange every 20 min and an automatic 12 h light/dark cycle (light on from 7:00 AM to 19:00 PM). The animals were fed a standard laboratory diet, and water was provided ad libitum. The inhibitory effects of SKF83959 on SERT, NET, and DAT Stably expressed transporter Chinese hamster ovary (CHO) cell lines were generated in our laboratory and have been previously used for compound activity tests [29] . These stablyexpressed transporter cell lines were cultured in a mixture of Dulbecco's modified Eagle's medium (DMEM) and F12 (1:1, v/v) supplemented with 10% fetal calf serum (FCS) and antibiotics (10 units/mL penicillin, 100 μg/mL streptomycin, and 100 μg/mL G418). The culture dishes were maintained in a 37 °C incubator with a humidified atmosphere of 5% CO 2 .
We first investigated the inhibitory effects of SKF83959 on the uptake activity of SERT. The assays were performed as previously described [30] . Briefly, SERT-expressing CHO cells were seeded in 24-well cluster plates (Corning; NY, USA) at a density of 1.0×10 6 cells per well. After 12 h, the culture medium was removed, and 20 μL of SKF83959 or DOV21947 (final concentration: 0.1 nmol/L-0.1 mmol/L) and 160 μL HBSS buffer (containing 10 μmol/L pargyline, 10 μmol/L tropolone, and 10 μmol/L ascorbic acid) were added. After 10 min of incubation, [ 3 H]-serotonin was added (final concentration: 2.4 nmol/L) for 10 min at 37 °C. The uptake was terminated by rinsing the cells three times with ice-cold PBS buffer. The cells were lysed using 0.1 mL of 2 mol/L NaOH. Nonspecific uptake was defined with Na + -free HBSS. The general procedures for norepinephrine and dopamine uptake were the same as those used for serotonin except for the different radiolabeled ligands [29] . To further characterize the effects of SKF83959, we analyzed the kinetics of SKF83959 and DOV21947 on the corresponding transporters. For the K t measurement, the corresponding cells were incubated with different concentrations of radiolabeled ligand ( where S denotes the radiolabeled ligand concentration (nmol/L), V max denotes the maximal reuptake capacity (cpm/min·10 6 cell), and K t denotes the Michaelis-Menten constant for the transporter-mediated transport (nmol/L).
Next, the K i parameter was assayed. The saturation curves were re-examined in the presence of SKF83959 or DOV21947. Depending on the inhibitory pattern (competitive or noncompetitive), the K i values were then calculated using the Michaelis-Menten competitive inhibition equation:
or noncompetitive inhibition equation:
where S denotes the radiolabeled ligand concentration (nmol/L), V max denotes the maximal reuptake capacity (cpm/ min·10 6 cell), I denotes the concentration of SKF83959 or DOV21947 (μmol/L), and K i denotes the inhibition constant of SKF83959 or DOV21947 for the transporters (μmol/L).
Forced swimming test
The forced swimming test was performed as previously described [31] . The mice were placed in a transparent cylindrical beaker (height, ~25 cm; internal diameter, 10 cm) containing water (22-24 °C) to a level of 15 cm. The water was always changed between trials. Thirty minutes before the test, SKF83959 or DOV21947 was intraperitoneally administered (2-8 mg/kg) to the mice. The immobility time was measured during a 5-min period by a trained observer who was blind to the treatment conditions. Each mouse was considered immobile if they were floating motionless or if they were only making the minimal amount of movements necessary to keep its head above the water surface.
Tail-suspension test
The tail suspension test was performed as previously described [32] . C57BL/6J mice were individually suspended 75 cm above the tabletop with an adhesive tape placed approximately 1 cm from the tip of the tail. The immobility duration was recorded for 6 min. Thirty minutes before the test, SKF83959 or DOV21947 was intraperitoneally administered (2-8 mg/kg). The duration of the immobility was measured by a trained observer according to the double-blind test rule. The mice were considered immobile only if they were hung passively and demonstrated no motion.
Data analysis
The IC 50 values were expressed as the mean [95% confidence interval (95% CI)]. The difference between the IC 50 was tested using weighted probit analysis. The other data were expressed as the mean±SEM. For multiple comparisons of the parameters, one-way ANOVA and the Dunnett's post-hoc test were used. Differences were considered significant if P<0.05. The data were analyzed using the Graphpad Prism software (GraphPad Software Inc, La Jolla, CA, USA, Version 5.0).
Results
Inhibition of SKF83959 on SERT, NET, and DAT First, we tested the maximal inhibitory effect of SKF83959 on the three transporters. We found that SKF83959 (100 μmol/L) completely blocked the uptake activity. Moreover, the maximal inhibitory effect of SKF83959 was similar to that of DOV21947 (t-test, P>0.05).
Next, we studied the concentration-response relationship for SKF83959-inhibited uptake activity on the respective transporter. As shown in Figure 1 and Table 1 , the IC 50 of SKF83959 for SERT was similar to that of DOV21947 (t-test, P>0.05), but the IC 50 values of SKF83959 for NET and DAT were greater than those of DOV21947 (t-test, P<0.05) .
These data clearly demonstrated that SKF83959 functions as a potent triple reuptake inhibitor.
Effects of SKF83959 on the uptake kinetics of SERT, NET, and DAT To further characterize the effects of SKF83959 on the three transporters, we analyzed the kinetics of the transporters and checked the effect of SKF83959 on the uptake kinetics. The relationship between the uptake activity and the substrate concentration was provided by the Michaelis-Menten equation.
As shown in Figure 2A and Table 2 , SKF83959 and DOV21947 did not alter V max (one-way ANOVA, P>0.05), but significantly increased the value of K t (one-way ANOVA, P<0.05), indicating that SKF83959 and DOV21947 were two competitive inhibitors for SERT. Moreover, the K i value of SKF83959 was not significantly different from that of DOV21947 (t-test, P>0.05).
However, in contrast to the effect on SERT, both SKF83959 and DOV21947 reduced the V max value (one-way ANOVA, P<0.05, compared to vehicle) but did not change the K t value (one-way ANOVA, P>0.05, compared to vehicle) in the NET uptake kinetics test, which was consistent with its noncompetitive pattern ( Figure 2B , Table 2 ). The K i of SKF83959 was greater than that of DOV21947 (t-test, P<0.05), indicating that the inhibitory activities of SKF83959 were weaker than that of DOV21947.
Similar to NET, SKF83959 also inhibited DAT in a noncompetitive manner. SKF83959 significantly decreased V max (t-test, P<0.05) without any change in K t (t-test, P>0.05). Interestingly, in contrast to SKF83959, DOV21947 inhibited DAT in a competitive manner ( Figure 2C , Table 2 ). The K i of SKF83959 was greater than that of DOV21947 (t-test, P<0.05), indicating that the inhibitory activities of SKF83959 were weaker than that of DOV21947.
SKF83959 elicits potent anti-depressant activity in animal models
Because SKF83959 is a novel potent triple reuptake inhibitor, we tested the anti-depressant activity of this drug in mice. The forced swimming and tail suspension tests are two widely used methods to detect the anti-depressant efficacy of experimental drugs.
As shown in Figure 3A , SKF83959 decreased the immobility time in the forced swimming test in a dose-dependent manner. For the vehicle treated-mice, the immobility time was 158.40±10.31 s. The immobility time was significantly decreased (one-way ANOVA, P<0.001) in mice treated with SKF83959. Importantly, the reductions in the immobility time produced by SKF83959 were comparable to that produced by DOV21947 at the same doses ( Figure 3A) .
Similarly, SKF83959 significantly reduced the immobility time in the tail suspension test ( Figure 3B , one-way ANOVA, P<0.001). In the vehicle group, the immobility time was 135.00±7.44 s. A significant decrease was observed with 2 mg/kg of SFK83959 treatment. Furthermore, the reductions in the immobility time produced by SKF83959 were comparable to those in the immobility time produced by DOV21947 at the same doses ( Figure 3B ). 
Discussion
In the present study, we found that SKF83959 was an effective inhibitor for the uptake activity of SERT, NET, and DAT. We further determined that SKF83959 functioned as a SERT competitive inhibitor, and behaved as a noncompetitive inhibitor for NET and DAT, which differed from the well-known triple uptake inhibitor DOV21947. Moreover, we provided convincing data demonstrating that SKF83959 was a potent antidepressant agent in the forced swimming test and tail suspension test in mice. The present study showed, for the first time, that SKF83959 is a novel triple uptake inhibitor that elicits an anti-depressant effect. This finding may provide a novel pharmacological mechanism for the understanding of various biological functions of this drug.
Increasing the synaptic availability of biogenic amines is one important strategy used in anti-depressant therapy [33] . Following the application of dual uptake inhibitors (prototypic tricyclic anti-depressants and serotonin/norepinephrine uptake inhibitors) and the selective serotonin uptake inhibitor, triple uptake inhibitors were recently found to be promising chemical entities for the treatment of depression [34] , including DOV21947, PRC200SS, and GSK136070F. DOV21947 has demonstrated effective anti-depressant activity in a Phase III clinical study [34] . In addition, the most recent clinical studies have shown that DOV21947 begins to exert its anti-depressant activity after only one week of treatment [35] . The mean baseline score on the Montgomery-Åsberg Depression Rating Scale (MADRS) was significantly higher than that on the placebotreated population. Our data indicated that SKF83959, with a benzazepine structure, is a novel and potent triple uptake inhibitor that elicits a comparable anti-depressant efficacy in vivo similar to DOV21947. Due to the difficulty in the design of triple uptake inhibitors [36] , the identification of a benzazepine-like structure as a novel category of triple uptake inhibitor may provide an alternative strategy in the development of anti-depressant drugs.
Analysis of the transporting kinetics of SKF83959 and DOV21947 revealed a significant difference between the two types of uptake inhibitors. We found that SKF83959 was a competitive inhibitor for SERT, but a noncompetitive inhibitor for NET and DAT. Consistent with previous reports [6] , we confirmed that DOV12947 was a competitive uptake inhibitor for DAT and SERT. Interestingly, we found that DOV21947 was a NET noncompetitive inhibitor, which has not been previously reported. Moreover, our data showed that the inhibitory potency of SKF83959 on SERT was similar to DOV21947, but was weaker on NET and DAT. Despite this difference, the same dose of SKF83959 and DOV21947 produced equivalent anti-depressant effects in different animal models (Figure 3) . However, whether the differential inhibitory patterns in the kinetics between the two drugs contribute to the anti-depres- 3 H]-dopamine was 1.6 nmol/L. The nonspecific uptake activity was determined using Na + -free HBSS solution and the specific uptake activity was normalized as 100%. Each experiment was replicated at least three times. The data were expressed as the mean±SEM. The parameters were obtained from Figure 1 . [6] . Our experiment was based on uptake kinetics, whereas that of Skilnick was based on receptor binding. Thus, the K i values between the two studies were completely different although they share a common symbol (K i ). In addition, the difference in the cell lines used (CHO vs HEK293) may also account for the discrepancy. It is well known that the IC 50 value is closely dependent on the transporter density in the cell membrane as well as the expression level of the transporters. In addition, the difference in the transporters of the species employed (human transporter and rat transporter) also npg produced some distinct potency in the in vitro cell models [10] . In summary, the present data indicated that SKF83959 displayed potent anti-depressant effects. The identification of SKF83959, a benzazepine structure, as a triple uptake inhibitor may provide a new avenue for the discovery of novel antidepressant drugs.
